Chronic obstructive pulmonary disease
Conditions
Interventions
Intervention group:A three-tiered hospital-community collaboration pharmacist intervention model based on risk stratification
Control group:Routine Management (Basic Inhalation Guidance + Outpatient Follow-up)
Sponsors
Drum Tower Hospital
Eligibility
Sex/Gender
All
Age
40 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 40 years; 2. Meets the diagnostic criteria for COPD according to the "Chinese Guidelines for the Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease (2021 Edition)" or the GOLD 2025 guidelines; 3. Condition is clinically stable (no acute exacerbations in the past 4 weeks); 4. Currently using at least one inhalation device for maintenance therapy (e.g., inhaled bronchodilators or inhaled corticosteroids); 5. At the start of the study, assessed to have improper inhaler use or insufficient medication adherence (e.g., incorrect inhalation technique identified at baseline examination, or poor adherence scale scores); 6. Possesses basic communication skills and can cooperate with questionnaires and follow-ups; 7. Voluntarily participates in the study and signs the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with severe comorbidities and an expected survival of less than 1 year (such as advanced malignant tumors, end-stage heart failure, etc.); 2. Patients with severe cognitive impairment or mental illness that prevents cooperation with the intervention; 3. Patients who have received systematic professional training on inhalation devices or pharmaceutical management guidance within the past year prior to the study (to avoid excessively high baseline levels being affected); 4. Other situations deemed unsuitable for inclusion in the study by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Inhalation device usage accuracy rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse Drug Reactions (ADRs) and Serious Adverse Events (SAEs);Test of Adherence to Inhalers; | — |
Countries
China
Contacts
Public ContactQiuhui Wu
Nanjing University Medical School Affiliated Drum Tower Hospital
Outcome results
None listed